Early research funded by the Children's Tumor Foundation has led to developments in schwannomatosis research. One award (2008) was for the development of the first mouse model for schwannomatosis with the same underlying gene mutations found in schwannomatosis patients. The second award (2011) was to support their use in a screening platform for schwannomatosis therapeutic agents.
The August issue of EMBO Molecular Medicine features an article authored by Children’s Tumor Foundation President and Chief Scientific Officer Annette Bakker, PhD, and Salvatore La Rosa, PhD, Children’s Tumor Foundation VP, Research & Development about the larger role foundations are playing within the rare disease research ecosystem. EMBO Molecular Medicine is a peer-reviewed, online open access journal dedicated to a new research discipline at the interface between clinical research and basic biology.
We are thrilled to announce that Children’s Tumor Foundation President and Chief Scientific Officer Annette Bakker, PhD, has been announced as a recipient of a 2017 RARE Champion of Hope award.
The NF Registry is delivering on its promise to be a valid and useful tool for both patients and researchers. This is the conclusion of an analysis published in the journal PLOS One in June 2017. Not only are thousands of patients from all over the world contributing their data to the Registry, it is being actively used, and appreciated, by researchers working on all forms of NF.
The NF Research Initiative (NFRI) at Boston Children’s Hospital has two open requests for applications: